AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30204730 — intervention group
Group type: COMPARATOR
Intervention: Verteporfin photodynamic therapy (Group III)
Number of subjects: 457
Study 30204730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections (Groups I/II)
Number of subjects: 457
Study 28010989 — intervention group
Group type: COMPARATOR
Intervention: Standard repair alone
Number of subjects: 1352
Study 28010989 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh augmentation
Number of subjects: 1352
Study 28010989 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft augmentation
Number of subjects: 1352
Study 25517761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 3 × 5 min occlusion at 220 mmHg
Number of subjects: 16
Study 25517761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) with 3 × 5 min occlusion at 50 mmHg
Number of subjects: 16
Study 25517761 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment with 3 × 5 min occlusion
Number of subjects: 16
Study 25517761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC) in female cohort
Number of subjects: 16
Study 23668624 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/day)
Number of subjects: 863
Study 23668624 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Behavioral Intervention (CBI)
Number of subjects: 863
Study 23668624 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone + CBI
Number of subjects: 863
Study 23668624 — intervention group
Group type: COMPARATOR
Intervention: Placebo Naltrexone
Number of subjects: 863
Study 21192150 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 334
Study 21192150 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 334
Study 21192150 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram or Fluoxetine (dose increase at week 6)
Number of subjects: 334
Study 21192150 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 334
Study 21192150 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI plus cognitive behavior therapy
Number of subjects: 334
Study 21192150 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine plus cognitive behavior therapy
Number of subjects: 334
Study 19167721 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated external defibrillators (AEDs)
Number of subjects: 60
Study 19167721 — intervention group
Group type: COMPARATOR
Intervention: Manual defibrillators (MDs)
Number of subjects: 60
Study 17123235 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg (GRA1) + 8 mg dexamethasone
Number of subjects: 738
Study 17123235 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 3 mg (GRA3) + 8 mg dexamethasone
Number of subjects: 738
Study 17123235 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg (OND8) + 8 mg dexamethasone
Number of subjects: 738
Study 15128726 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (received a three-item questionnaire)
Number of subjects: 251
Study 15128726 — intervention group
Group type: COMPARATOR
Intervention: Intervention group (compared with a similar group of 151 patients observed during a 2 month period preceding the study)
Number of subjects: 251
Study 11486981 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic outcomes monitoring (TOM)
Number of subjects: 350
Study 11486981 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TOM)
Number of subjects: 350
Study 9482177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen (150 mg, twice a day for 2 weeks)
Number of subjects: 286
Study 9482177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 286
Study 9482177 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen
Number of subjects: 286
Study 8059693 — intervention group
Group type: COMPARATOR
Intervention: Volume loading (mean 400 ml saline solution)
Number of subjects: 11
Study 8059693 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 11
Study 8059693 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (10 micrograms/kg/min)
Number of subjects: 11
Study 3143264 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin and glyburide
Number of subjects: 20
Study 3143264 — intervention group
Group type: COMPARATOR
Intervention: Insulin plus placebo
Number of subjects: 20
Study 31999774 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Weighted Imaging (DWI)
Number of subjects: 30
Study 31999774 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-Only plus Contrast (WOC)
Number of subjects: 30
Study 31999774 — intervention group
Group type: COMPARATOR
Intervention: Fat-Only (FO)
Number of subjects: 30
Study 31999774 — intervention group
Group type: COMPARATOR
Intervention: Fat-Only plus Contrast (FOC)
Number of subjects: 30
Study 29035128 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma homocysteine levels (highest vs lowest quartile)
Number of subjects: 292
Study 29035128 — intervention group
Group type: EXPERIMENTAL
Intervention: Total folate intake (quartiles)
Number of subjects: 292
Study 29035128 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake from food (quartiles)
Number of subjects: 292
Study 29035128 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine intake (quartiles)
Number of subjects: 292
Study 29121326 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased FSH dose (225/450 IU/day)
Number of subjects: 511
Study 29121326 — intervention group
Group type: COMPARATOR
Intervention: Standard FSH dose (150 IU/day)
Number of subjects: 511
Study 26694150 — intervention group
Group type: COMPARATOR
Intervention: 80kV/300mAs (Group 1; n. 20)
Number of subjects: 60
Study 26694150 — intervention group
Group type: COMPARATOR
Intervention: 80kV/400mAs (Group 2; n. 20)
Number of subjects: 60
Study 26694150 — intervention group
Group type: COMPARATOR
Intervention: 80kV/500mAs (Group 3; n. 20)
Number of subjects: 60
Study 26694150 — intervention group
Group type: EXPERIMENTAL
Intervention: 120kV (all patients)
Number of subjects: 60
Study 23669884 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered interpersonal psychotherapy (IPT)
Number of subjects: 1843
Study 23669884 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (CBT)
Number of subjects: 1843
Study 23669884 — intervention group
Group type: COMPARATOR
Intervention: Active control treatment (MoodGYM)
Number of subjects: 1843
Study 21878788 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term dynamic therapy
Number of subjects: 50
Study 21878788 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy
Number of subjects: 50
Study 19198042 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncircumcised males during unprotected sexual contact
Number of subjects: 0
Study 19198042 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HSV-2 in either partner
Number of subjects: 0
Study 19198042 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HIV in either partner
Number of subjects: 0
Study 19198042 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 0
Study 16858633 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeking Safety (SS)
Number of subjects: 33
Study 16858633 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 33
Study 15273918 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy in hypogonadal patients
Number of subjects: 88
Study 15273918 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy of calcium and vitamin D
Number of subjects: 88
Study 11500195 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 189
Study 11500195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 11500195 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 189
Study 9288515 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent aortic cross clamping with fibrillation
Number of subjects: 24
Study 9288515 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cold crystalloid cardioplegia
Number of subjects: 24
Study 1774656 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% hydroxypropyl methylcellulose (Occucoat)
Number of subjects: 222
Study 1774656 — intervention group
Group type: COMPARATOR
Intervention: Sodium hyaluronate (Healon)
Number of subjects: 222
Study 6752712 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (40 mg twice daily)
Number of subjects: 1103
Study 6752712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1103
Study 30864259 — intervention group
Group type: EXPERIMENTAL
Intervention: EpiFix (dehydrated human amnion/chorion membrane allograft)
Number of subjects: 128
Study 30864259 — intervention group
Group type: COMPARATOR
Intervention: Standard care (moist dressings and multi-layer compression)
Number of subjects: 128
Study 29089066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotilaner (Credelio™) at a dose of 20 mg/kg, administered orally 30 minutes after feeding.
Number of subjects: 64
Study 29089066 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group (Groups 5 to 8).
Number of subjects: 64
Study 26800687 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year exercise program with 200 min of physical activity (PA) per week
Number of subjects: 743
Study 26800687 — intervention group
Group type: COMPARATOR
Intervention: Control group with 60 min of physical activity (PA) per week
Number of subjects: 743
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16 L1
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18 L1
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV31 L1
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV18
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV52 and HPV58
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual exposure
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: Current or former smokers
Number of subjects: 2464
Study 23588935 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex assay
Number of subjects: 2464
Study 21835280 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg dalcetrapib daily for 24 months
Number of subjects: 130
Study 21835280 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 24 months
Number of subjects: 130
Study 19252920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar vessel sealing (BVS; BiClamp)
Number of subjects: 175
Study 19252920 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture ligation
Number of subjects: 175
Study 16703780 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products only
Number of subjects: 1089
Study 16703780 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral doxycycline
Number of subjects: 1089
Study 16703780 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5%/8.5% benzoyl peroxide in a 10% urea vehicle products along with oral minocycline
Number of subjects: 1089
Study 14654718 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.23 mg/kg/week (group A)
Number of subjects: 26
Study 14654718 — intervention group
Group type: EXPERIMENTAL
Intervention: GH 0.46 mg/kg/week (group B)
Number of subjects: 26
Study 14654718 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy (both groups)
Number of subjects: 26
Study 11575685 — intervention group
Group type: EXPERIMENTAL
Intervention: Web survey group
Number of subjects: 0
Study 11575685 — intervention group
Group type: COMPARATOR
Intervention: Mail survey group
Number of subjects: 0
Study 9671870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 250 mg once daily
Number of subjects: 186
Study 9671870 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily
Number of subjects: 186
Study 9671870 — intervention group
Group type: COMPARATOR
Intervention: Lomefloxacin 400 mg once daily
Number of subjects: 186
Study 7836549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered after an 8-hour overnight fast
Number of subjects: 0
Study 7836549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered 1 hour before a standard breakfast
Number of subjects: 0
Study 7836549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered 15 minutes after beginning a standard breakfast
Number of subjects: 0
Study 7836549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine (Cognex, THA) administered 2 hours after completion of a standard breakfast
Number of subjects: 0
Study 3046277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol, 160 mg twice daily
Number of subjects: 10
Study 3046277 — intervention group
Group type: COMPARATOR
Intervention: Atenolol, 50 mg twice daily
Number of subjects: 10
Study 3046277 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sotalol, 100 mg
Number of subjects: 10
Study 3046277 — intervention group
Group type: COMPARATOR
Intervention: Intravenous atenolol, 10 mg
Number of subjects: 10
Study 30232383 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermia
Number of subjects: 21
Study 30232383 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐194‐5p mimic
Number of subjects: 21
Study 30232383 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐194‐5p
Number of subjects: 21
Study 26881447 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram + CBT (16 sessions)
Number of subjects: 42
Study 26881447 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (without CBT)
Number of subjects: 42
Study 25919121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine in extensive/ultrarapid metabolizers
Number of subjects: 1936
Study 25919121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine in intermediate metabolizers
Number of subjects: 1936
Study 25919121 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine in poor metabolizers
Number of subjects: 1936
Study 23650294 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate 0.5% gel
Number of subjects: 41
Study 23650294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 21068676 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (PEG-creatine, 5 g·d)
Number of subjects: 22
Study 21068676 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin powder, 5 g·d)
Number of subjects: 22
Study 18222192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Number of subjects: 184
Study 18222192 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 184
Study 18222192 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 184
Study 16360926 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐15 (TSUMURA Orengedokuto Extract Granules)
Number of subjects: 265
Study 16360926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 12675866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade of the renin-angiotensin system (RAS) with irbesartan 300 mg (once daily) and enalapril 40 mg (once daily)
Number of subjects: 24
Study 12675866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual blockade of the renin-angiotensin system (RAS)
Number of subjects: 24
Study 12675866 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors + placebo
Number of subjects: 24
Study 10963287 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy (SIT) plus medical treatment
Number of subjects: 962
Study 10963287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962
Study 9151611 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage IMZ implant placement
Number of subjects: 0
Study 9151611 — intervention group
Group type: COMPARATOR
Intervention: Two-stage IMZ implant placement
Number of subjects: 0
Study 8403954 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics (tobramycin, polymyxin E, amphotericin B, vancomycin)
Number of subjects: 123
Study 8403954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (suspension of fluid and paste without antibiotics)
Number of subjects: 123
Study 2885854 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole (10 mg per day)
Number of subjects: 42
Study 2885854 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine (120 mg per day)
Number of subjects: 42
Study 29193563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8213
Study 29193563 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8213
Study 29193563 — intervention group
Group type: EXPERIMENTAL
Intervention: SUA quintiles (Q5 vs. Q1)
Number of subjects: 8213
Study 26841278 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathy-feedback VP
Number of subjects: 70
Study 26841278 — intervention group
Group type: EXPERIMENTAL
Intervention: Backstory VP
Number of subjects: 70
Study 26841278 — intervention group
Group type: COMPARATOR
Intervention: Control VP
Number of subjects: 70
Study 25020061 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (72 hours)
Number of subjects: 8
Study 25020061 — intervention group
Group type: COMPARATOR
Intervention: Control (Postabsorptive state)
Number of subjects: 8
Study 22941116 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatic symptom burden reduction
Number of subjects: 405
Study 20864555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-polyphenol diet (PSPL group)
Number of subjects: 15
Study 20864555 — intervention group
Group type: COMPARATOR
Intervention: Low-polyphenol diet (control group)
Number of subjects: 15
Study 18211927 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once a day
Number of subjects: 60
Study 18211927 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 60
Study 18211927 — intervention group
Group type: COMPARATOR
Intervention: Deep Sclerectomy with Collagen Implant (DSCI)
Number of subjects: 60
Study 16357838 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 349
Study 16357838 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 349
Study 16357838 — intervention group
Group type: EXPERIMENTAL
Intervention: ASCT
Number of subjects: 349
Study 14615655 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 2947
Study 11106136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg)
Number of subjects: 353
Study 11106136 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20-40 mg)
Number of subjects: 353
Study 11106136 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 353
Study 11106136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 353
Study 11106136 — intervention group
Group type: EXPERIMENTAL
Intervention: Early response (25% reduction in MADRS scores at week 2)
Number of subjects: 353
Study 8626359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (mean dose at endpoint = 379 mg/day)
Number of subjects: 247
Study 8626359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 8626359 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 247
Study 1336527 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril at 25 mg twice a day
Number of subjects: 265
Study 1336527 — intervention group
Group type: COMPARATOR
Intervention: Atenolol at 50 mg once a day
Number of subjects: 265
Study 6518669 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate dietary salt restriction
Number of subjects: 28
Study 6518669 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 28
Study 30972581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine or group cognitive-behavioral therapy for 14 weeks
Number of subjects: 29
Study 30972581 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 29
Study 29314872 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adherent tape
Number of subjects: 29
Study 29314872 — intervention group
Group type: EXPERIMENTAL
Intervention: Lace-up ankle brace
Number of subjects: 29
Study 26815709 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 60
Study 26815709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24361082 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut oral immunotherapy (OIT)
Number of subjects: 24
Study 21702044 — intervention group
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 258
Study 20551371 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 2331
Study 20551371 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2331
Study 18698012 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin (162 mg)
Number of subjects: 9
Study 18698012 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical methyl salicylate (5 g of 30% preparation)
Number of subjects: 9
Study 16385104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute treatment strategies for migraine
Number of subjects: 0
Study 16385104 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment strategies for migraine
Number of subjects: 0
Study 12450883 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein, high-methionine diet (HP: 22% of total energy, 2.7 g methionine/d; n = 25)
Number of subjects: 65
Study 12450883 — intervention group
Group type: COMPARATOR
Intervention: Low-protein, low-methionine diet (LP: 12% of total energy, 1.4 g methionine/d; n = 25)
Number of subjects: 65
Study 12450883 — intervention group
Group type: COMPARATOR
Intervention: Control diet (intermediate protein content; n = 15)
Number of subjects: 65
Study 10369491 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron (14 mg/d) and 60 mg/d vitamin C (Group A)
Number of subjects: 40